Description
Levobupivacaine-d9 is intended for use as an internal standard for the quantification of levobupivacaine (Item No. 31596) by GC- or LC-MS. Levobupivacaine is a sodium channel blocker and local anesthetic, as well as the levorotary stereoisomer of bupivacaine (Item No. 16618).1,2,3 It inhibits cardiac sodium channel currents (INa) by 57.8% in isolated guinea pig ventricular myocytes when used at a concentration of 10 μM.1 Levobupivacaine (10 μM) reduces the maximal rate of depolarization (Vmax) and action potential duration to 76.7 and 83.4% of controls, respectively, in isolated guinea pig papillary muscle.2 It induces a complete block of proprioception, motor function, and nociception in the hindleg of rats when administered at a dose of 7.7 mM by percutaneous injection into the sciatic nerve.3WARNING This product is not for human or veterinary use.
References
[1] C VALENZUELA. Stereoselective block of cardiac sodium channels by bupivacaine in guinea pig ventricular myocytes.[J]. Circulation, 1995, 92 10: 3014-3024. DOI:
10.1161/01.cir.92.10.3014[2] FILIP VANHOUTTE. Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea-pig papillary muscle[J]. British Journal of Pharmacology, 1991, 103 1: 1275-1281. DOI:
10.1111/j.1476-5381.1991.tb12336.x[3] CATHERINE J SINNOTT B.A. Gary R S Ph D. Levobupivacaine versus ropivacaine for sciatic nerve block in the rat[J]. Regional Anesthesia and Pain Medicine, 2003, 28 4: Pages 294-303. DOI:
10.1016/s1098-7339(03)00188-3
